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Abstract
Well over six decades since its first description, the Rheumatoid Factor (RF)—autoantibodies recognizing Fc (constant)
portion of IgG through their own Fab (antigen binding variable segments)—is believed to have come of age. Autoimmune
pancreatitis is a unique form of pancreatitis, biologically characterized by an elevated serum IgG4 concentration. Given the
fact that IgG4 myeloma proteins can act as RF, we initially hypothesized that IgG4 in autoimmune pancreatitis might do
likewise, hence potentially contributing to disease pathogenesis. Indeed Western blotting clearly showed that IgG4 binds to
IgG1 k, IgG2 k, IgG3 k myeloma proteins, as well as to IgG Fc, in line with a typical RF activity. Further experiments however
unraveled the unexpected fact that unlike hitherto known RF, IgG4 does not engage IgG Fc through its Fab, but its very own
Fc. These data therefore collectively describe a Novel RF (NRF) in autoimmune pancreatitis. In the future, the relevance of
NRF, beyond autoimmune pancreatitis, in both diagnosis/prognosis as well as pathophysiology of autoimmune and other
systemic diseases where IgG4’s role seems paramount, needs to be systematically assessed.
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Introduction
Despite the identification or the generation of numerous natural
and/or transgenic/gene deficient animal models of autoimmunity,
the translation of the clinical symptomatology and or biological/
immunological pathophysiology to man and vice versa has led to
few tangible results in the fields of diagnosis/prognosis and/or
treatment of human autoimmune diseases [1,2]. Perhaps the major
hurdle in this quest, at least in man, is the extraordinary
complexity, if not uniqueness, of each autoimmune disorder
leaving a few common denominators helping to understand the
pathology as a whole. One such common denominator are
autoantibodies, present–albeit in different titers and against
different targets–in virtually all human autoimmune disorders
[3]. Among these, the Rheumatoid Factor (RF), along with
antinuclear antibodies are the most prominent ones, both in terms
of frequency and/or possible role in pathogenesis or yet resolvance
of autoimmune diseases. RF are anti-IgG antibodies of mainly IgM
but also IgG (or other) isotypes [4]. The interaction between the RF
and IgG is well documented; the RF Fab (antigen binding site)
recognizes IgG Fc (constant) segment most frequently at the level of
Cc2-Cc3 segments [5].
Autoimmune pancreatitis is an emerging syndromic entity
characterized by several cardinal features distinctive from chronic
pancreatitis (cf. infra)[6,7]. The latter, mainly caused by alcohol
abuse, can result in severe impairment of exocrine and endocrine
pancreatic functions. Imaging findings include pancreatic stones
and irregular dilatation of the pancreatic duct. Autoimmune
pancreatitis is an alternative form of chronic pancreatitis marked
by irregular narrowing of the main pancreatic duct and swelling of
the pancreatic parenchyma. The disease is associated with various
autoimmune features including hypergammaglobulinemia, histo-
logical evidence of lymphoplasmacytic inflammation, occasional
coexistence of other autoimmune and/or systemic diseases, and a
favorable response to glucocorticoid treatment [8,9]. Typical
clinical features include relative preponderance in elderly male,
high frequency of obstructive jaundice-which incidentally together
with the swelling of the pancreatic parenchyma can lead to
erroneous diagnosis as pancreatic cancer; leading to unnecessary
surgery [9–11]. They also include extra-pancreatic manifestations
i.e. sclerosing cholangitis, [12] sialadenitis, [13] retroperitoneal
fibrosis, [14] hilar lymphadenopathy, [15] hypothyroidism,[16]
tubulointerstitial nephritis [17], hypophysitis [18] and prostatitis
[19]. The variety of these extra-pancreatic lesions suggest, the
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defining a previously unappreciated systemic disease [14,20].
Biologically, the most salient feature of autoimmune pancreatitis
was our previous report of a specific augmentation of serum IgG4
levels [21]. IgG4, quantitatively the least prevalent of all human
IgG subclasses, has two unique features: not being able to activate
the classical complement pathway and to bind antigen with low
affinity [22]. It has been previously reported to be specifically
involved in a number of disorders among which the following are
relevant both in terms of prevalence as well as public health. They
include parasitic infestation [23], various forms of atopy [24],
idiosyncratic drug-induced hepatitis [25], besides the well-
established role of anti-desmoglein IgG4 as bona fide autoantibodies
in pemphigus vulgaris and pemphigus foliaceus [26].
Here we initially aimed to confirm the antigenic reactivity of
IgG4 as RF. However the findings detailed below led to the
unexpected identification of a novel topology of autoantigen-
autoantibody interaction, hereafter called Novel RF (NRF), in
contrast to the original RF [27–29], consequently re-named
Classical RF (CRF).
Methods
Patients, controls and diagnostic criteria
Serum samples were obtained from 65 autoimmune pancreatitis
patients-54 men and 11 women-aged 38–79 years (median
62.4 years) as well as the following ‘‘control’’ populations: 111
suffering from alcoholic or idiopathic chronic pancreatitis, 96
diagnosed with pancreatic cancer, 40 with autoimmune hepatitis,
39 with primary biliary cirrhosis, 20 with primary sclerosing
cholangitis, 13 with systemic lupus erythematosus, 7 with Sjo ¨gren’s
syndrome, 3 with progressive systemic sclerosis and from 130
healthy subjects. All sera were stored at 220uC prior to analysis.
All patients with autoimmune pancreatitis fulfilled the revised
diagnostic criteria proposed by Japan’s Pancreas Society. [30]
including the following biological and radiological findings:
elevated serum immunoglobulin (including IgG4 as established
by single radial immunodiffusion; see below) and/or positive
autoantibodies e.g. anti-nuclear antibody and RF (N-Assay TIA
RF Nittobo (Nitto Boseki Co., Ltd, Koriyama, Japan) and
irregular narrowing of the main pancreatic duct as evidenced by
endoscopic retrograde cholangio-pancreatography as well as an
enlarged pancreas as assessed by ultrasonography, computed
tomography, or magnetic resonance imaging. Histological confir-
mation of lymphoplasmacytic infiltration and fibrosis in the
pancreas was obtained for 13 of these autoimmune pancreatitis
patients. All 111 patients with alcoholic or idiopathic chronic
pancreatitis had either marked irregular dilation of the main
pancreatic duct or calcification of the pancreas. The diagnosis of
pancreatic cancer was confirmed by histology in 38 patients and
by both typical imaging findings and the clinical course in the
remaining 58 patients. All subjects (patients and controls) provided
written informed consent for procedures performed in this study
which was approved by Ethics Committee of the Shinshu
University School of Medicine.
Western blotting
Throughout experiments, immunoglobulin samples were resolved
on 10 % sodium dodecyl sulfate (SDS)- polyacrylamide gels (PAGE)
under reducing conditions followed by transfer onto polyvinylidene
difluoride membranes (Bio Rad 163-0181, Hercules, CA). The blots
were incubated with a variety of monoclonal antibodies (1:1000
dilutions) (see infra) and developed using enhanced chemilumines-
cence (ECL, Amersham Pharmacia Biotech).
Antibodies
The following human myeloma immunoglobulins were used:
IgG1k,I g G 2 k,I g G 3 k,I g G 4 k, IgA1k, IgA2k,I g M k (myeloma
protein, Binding-Site, Birmingham, UK), IgDk (myeloma plasma,
Calbiochem, La Jolla, CA), IgEl (myeloma plasma, Athens
Research & Technology, Athens GA), IgG F(ab’)2 (MP Biomedicals,
Inc. Aurora, Ohio) and IgG Fc (Athens Research & Technology,
Athens, GA) (Fc fragments were produced by papain digestion and
affinity chromatography of normal human IgG, itself isolated upon
fractionation and DEAE chromatography). The specificity of each
immunoglobulin sample was confirmed by Western blotting, where
membranes were incubated with the corresponding peroxidase-
conjugated antibody for each immunoglobulin isotype. For the
totality of experiments the following peroxidase-conjugated second
antibodies were used: mouse anti-human IgG1 (Zymed 05-3320,
South San Francisco, CA), mouse anti- human IgG2 (South Biotech
9060-05,Birmingham,AL),mouse anti-humanIgG3 (SouthBiotech
9210-05), mouse anti-human IgG4(SouthBiotech9200-05) (ofIgG1
isotype which reacts to the Fc portion of IgG4), goat anti-human IgA
(Zymed 62-7420), goat anti-human IgM (South Biotech 2020-05),
goat anti-humanIgD (BiosourceAHI0204, Camarillo,CA) and goat
anti-human IgE (Biosource AHI0504). Finally, goat anti-human k
light chain (Bethyl Laboratories, Inc, A80115P) was used to detect
IgG4 F(ab’)2.
Immunoglobulin preparations
In order to use an identical patient serum in all experiments, the
autoimmune pancreatitis sera used was indeed a pool derived from
all 65 patients (500 mlo fe a c hs e r u m 665=32.5 ml of pooled
serum).The IgG4concentration of this pooled serum was755 mg/dl
as defined by single radial immunodiffusion (Human IgG Subclass
Single Dilution; BINDARID
TM Kits; the Binding Site Limited,
Birmingham, UK). This value was further used to construct a
standard curve for ELISA (see infra). To confirm the reactivity of the
patients’IgG4toFcfractionsofIgG1,IgG2and IgG3;apreparation
of IgG Fc lacking IgG4 Fc was needed. For such IgG Fc was first
absorbed by affinity chromatography where the column was bound
with anti-IgG4 antibody (The Binding Site Limited, Birmingham,
UK). The resultant IgG Fc depleted of IgG4 Fc was then used in
Western blotting in addition to intact IgG Fc. IgG4 Fc and IgG4
F(ab’)2 were generated through papain [31] and pepsin treatments
[32] of purified IgG4 (extracted from pooled patient sera by affinity
chromatography as described above) respectively. The step-by-step
methodology is provided in Figure S1.
ELISA
The capacity of IgG4 to act as RF was assessed by examining its
binding capacity for human IgG1 or IgG2 or IgG3 in ELISA. Micro
ELISA plates (Nunc immunoplate 446612, Rochester, NY) were
coated with human myeloma IgG1k, IgG2k or IgG3k (1 mg/well)
proteins. Plates were washed and then blocked with 1% bovine
serum albumin (BSA) in phosphate-buffered saline (PBS) containing
10 mmole of ethylene diamine tetra-acetic acid (EDTA). After
another wash, serum samples were diluted to 1:5000 and added.
Immobilized complexes were then incubated with peroxidase-
conjugated anti-human IgG4 monoclonal antibody in enzyme
conjugate stabilizer solution (Stab-ELISA-rHRP Diluent/Stabilizer,
Cygnus Technologies I-035, Southport, NC) (1:2000 dilution). The
enzyme bound to the wells was incubated in the dark with
tetramethylbenzidine substrate solution (TMB One-component
Microwell Peroxidase Substrate, Kirkegaard & Perry Laboratories
53-00-01, Gaithersburg, ML). The reaction was halted by the
addition of stop solution (TMB One-Component Stop Solution
Kirkegaard&PerryLaboratories50-85-05)andtheplatewasreadat
A Novel RF
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autoimmune pancreatitis patients were serially diluted from 39 to
10,000 ng/ml of IgG4 and the optical density for each IgG4 value
was plotted. The optical density of bound IgG4 concentration in
each serum sample was converted to an absolute IgG4 value using
this standard curve. The concentrations of standards were expressed
as IgG4 values from the pooled patient sera. The linear correlation
was obtained for each assay system between the absorbance of IgG4
boundtoeachIgGsubclassandtheIgG4valuefromthepooledsera.
The intra-assay variation was less than 5.0%, and the inter-assay
variation less than 7.5%. The HRP-conjugated second antibody
reacted minimally to coated myeloma proteins.
Results
The additive ‘‘autoimmune’’ in ‘‘autoimmune pancreatitis’’
stems from several lines of (indirect) evidence. These include a
significant association of susceptibility to the disease with premier
immune loci i.e. the HLA DRB1*0405-DQB1*0401 haplotype
[33,34] and the Fc receptor-like gene 3 (FCRL3) [35] as well as an
augmented serum IgG4 concentrations-which correlates with
disease activity [21] and parallels an abundant IgG4-bearing
plasma cell infiltration of affected tissues [14]. Given the
paramount nature of IgG4 elevation in the disease, our effort
converged on its relevance and based on the previous knowledge
of myeloma IgG4 being able to act as RF, our investigations first
aimed to replicate this aspect with this time non-clonal IgG4
present in autoimmune pancreatitis and eventually in other
pathological or physiological conditions.
We first used Western blotting to explore the Ig–Ig interaction
patterns of autoimmune pancreatitis patients’ IgG4. We initially
were able to show that IgG4 was able to bind to human IgG1,
IgG2, IgG3 and IgG Fc but not to human IgA, IgM, IgD, IgE and
IgG Fab, hence defining it as a de facto RF. In order to do so, we
first confirmed the identity of each immunoglobulin myeloma
protein used in experiments-IgG1k, IgG2k, IgG3k, IgA1k, IgA2k,
IgMk, IgDk and IgEl-through reactivity with the corresponding
HRP-labeled anti-Ig antibody (Figure 1a). As with other HRP-
labeled anti-immunoglobulin antibodies, HRP-labeled anti-IgG4
Fc reacted to IgG4k myeloma protein and to IgG Fc, but not to
IgG Fc lacking IgG4 Fc (Figure 1b). After an identical membrane
(as to Figure 1a) was exposed this time first to the pooled sera of
autoimmune pancreatitis patients, HRP-labeled anti-IgG4 anti-
body reacted to IgG1k, IgG2k, IgG3k, IgG Fc, and to a purified
IgG Fc lacking IgG4 Fc, but not to other human immunoglobulins
or to an IgG F(ab’)2 (it should be also noted that the reactivity of
HRP-labeled anti-IgG4 antibody to IgG4k seems to be amplified
upon exposure to autoimmune pancreatitis sera). These results
hence indicate that IgG4 from autoimmune pancreatitis patients is
able to bind IgG1k, IgG2k and IgG3k as well as IgG Fc (and
Figure 1. Reactivity of human IgG4 to various immunoglobulin classes and subclasses. Western blot analysis indicates the reactivity of
IgG4 in pooled sera of patients with autoimmune pancreatitis to various human immunoglobulin subclasses. (A) The identity of each commercially-
purchased immunoglobulin myeloma protein was confirmed upon reaction with the corresponding HRP-labeled anti-isotype antibodies respectively
i.e. IgG1k, IgG2k, IgG3k, IgA1k, IgA2k, IgMk, IgDk and IgEl (B) Similarly HRP-labeled antibody against IgG4 Fc specifically reacted to IgG4k. It also
reacted to IgG Fc (faint band on the right panel) but not to IgG Fab or yet Ig Fc lacking IgG4 Fc. (C) An identical membrane (to panel A) was subjected
this time, first, to pooled autoimmune pancreatitis sera and then to HRP-labeled anti-IgG4 Fc antibody which in contrast to panel B, reacted to IgG1k,
IgG2k, IgG3k, IgG Fc and affinity-purified IgG Fc lacking IgG4 Fc, but not to other human immunoglobulins and IgG Fab, hence establishing the fact
that patient IgG4 reacts to IgG1,2 and 3 Fc (additional bands at 220 kDa and about 38 kDa are likely aggregation or degradation products of IgG4).
Experiments were repeated three times with identical results and the pooled serum was used at 1:1000 dilution.
doi:10.1371/journal.pone.0001637.g001
A Novel RF
PLoS ONE | www.plosone.org 3 February 2008 | Volume 3 | Issue 2 | e1637perhaps to IgG4k myeloma protein itself) (Figure 1c) (it should be
noted that several individual sera were equally tested and gave
similar results as the pooled serum).
Having established that IgG4 recognizes IgG Fc, we next
examined whether IgG4’s Fc or Fab portion reacts to IgG Fc. A
preparation of IgG Fc that lacked IgG4 Fc was resolved on 10 %
SDS-PAGE and blotted. As expected, HRP-labeled anti-IgG4 Fc
or HRP-labeled anti-k light-chain showed no reactivity to this
preparation (Figure 2, lanes 1 and 2 respectively). However after
prior exposure to purified IgG4 or IgG4 Fc, HRP-labeled anti-
IgG4 Fc reacted strongly with this IgG Fc lacking IgG4 Fc
(Figure 2) whereas HRP-labeled anti-human k light-chain did not
interact with IgG Fc lacking IgG4 Fc after incubation with IgG4
F(ab’)2 (Figure 2, lane 4). These results collectively indicate that the
Fc portion of IgG4, rather than the Fab portion, binds to IgG Fc,
and that the binding of IgG4 to IgG is not attributable to the
autoantibody activity of IgG4 i.e. via Fab.
This Fc-Fc interaction is a novel finding and therefore we have
decided to name it Novel RF (NRF) in contrast to the ‘‘original’’
RF hereafter termed Classical RF (CRF). It was now worthwhile
to investigate the relevance of NRF in vivo. We first sought to
confirm by ELISA that each autoimmune pancreatitis patient’s
serum IgG4 does act as a Novel RF, by examining its binding
capacity to human IgG1 or IgG2 or IgG3. Serum IgG4 bound to
IgG1 was undetectable (or at very low levels) in 130 healthy
controls as well as patients with other autoimmune diseases
(n=119; cf. supra) including autoimmune hepatitis, primary
biliary cirrhosis, primary sclerosing cholangitis, systemic lupus
erythematosus and Sjo ¨gren’s syndrome (Figure 3, Table 1) or
other pancreatic affections i.e. chronic pancreatitis and pancreatic
cancer; all in contrast to a cohort of autoimmune pancreatitis
patients which harbored a significantly elevated concentration of
IgG4. Figure 4 clearly depicts two important facts with regards to
IgG4: firstly that indeed it does show NRF activity in the sense that
its serum concentration is in near perfect correlation with its
capacity to bind IgG1 (Figure 4a) and that this NRF activity is in
total discordance with that of the CRF i.e. no correlation with
IgG1 binding and CRF (Figure 4b). Given the almost perfect
correlation of IgG4 concentration to that of the functional IgG1
binding we chose to pursue with this latter as it depicts a functional
activity rather than just a ‘‘passive’’ concentration (Figure 4). As
depicted in Figure 3 and Table 1 high serum IgG4 concentrations
able to bind to IgG1 were detected in most samples from the
patients with autoimmune pancreatitis (median 269, range 0–
4,185 mg/dl), and the concentrations were significantly higher
than those observed in other selected diseases (Figure 3, Table 1).
Finally, assays of IgG4 bound to IgG2 or IgG3 showed results that
were similar to the results of the assays of IgG4 bound to IgG1
(Table 1). Inversely however neither IgG1, 2 or 3 did show any
NRF activity (unpublished data) i.e. IgG subclasses other than
IgG4 did not have the ability to bind to IgG1–4.
Discussion
Although some preliminary reports had suggested the presence
of pathogenic autoantibodies against specific pancreatic antigens,
[36,37] there is little evidence to conclude for IgG4 autoantibodies
to have a direct role in the pathogenesis of autoimmune
pancreatitis. This is in contrast to the case of pemphigus where
recognition of skin autoantigens (desmogleins) by IgG4 is at the
origin of the disease process [38]. Accordingly, we explored
alternative ways by which IgG4 could intervene in this process.
Based on the fact that several monoclonal (myeloma) IgG4
proteins do show the capacity to act as RF [39] we aimed to
ascertain whether serum (polyclonal) IgG4 in autoimmune
pancreatitis, does in fact act as RF, that is commonly defined as
an autoantibody which recognizes IgG Fc through its Fab [3].
Western blot analysis showed that IgG4 did indeed bind to
IgG1k, IgG2k, IgG3k and IgG Fc, hence acting, till this stage, as a
de facto RF. However, and surprisingly, IgG4 binding to IgG Fc
was due to its Fc, rather than to its Fab. This is formally
inconsistent with the simplest definition of an autoantibody that is
an immunoglobulin recognizing a self antigen through its variable,
antigen binding Fab, and consequently that of a RF i.e. an
autoantibody recognizing IgG Fc. Based on this contention, but
unwilling to introduce yet a new nomenclature, we propose for this
new Ig-Ig interaction to be called Novel RF (NRF) in contrast to
the original finding [27,28], subsequently called Classical RF
(CRF) (it should be noted that originally, the term RF was used as
an alternate for ‘‘Rheumatoid Arthritis Serum’’ prior to any
knowledge as to its fine identity and structural mode of action; see
[29]). Importantly however, any overlap between NRF and CRF
could be excluded based on the following arguments: (a) Western
blotting shows no IgG4 Fab- Ig Fc (CRF) interaction and (b)
ELISA showed that serum level of IgG4 bound to each IgG
subclass correlated well with the serum IgG4 level itself (i.e. the
totality of IgG4-Ig interaction is through Fc-Fc engagement), and
(c) the reciprocal absence of any link between IgG-bound IgG4
levels and RF, excluding therefore any CRF reactivity (Figure 5). It
should be also reminded that a previous report, albeit in vitro, did
show through domain swapping experiments that the binding of a
Figure 2. The topology of IgG4–IgG interaction. Western blotting
was used to establish whether the Fc or the Fab portion(s) of IgG4
reacted to IgG Fc. IgG Fc lacking IgG4 Fc was blotted on each lane. HRP-
labeled anti-human IgG4 Fc or HRP-labeled anti-human k light-chain
showed no reactivity to IgG Fc lacking IgG4 Fc (lanes 1 and 2). HRP-
labeled anti-IgG4 Fc antibody reacted to lanes 3 and 5, which were
previously incubated with purified IgG4 and IgG4 Fc, respectively. HRP-
labeled anti-human k light-chain had no reactivity to lane 4, which was
incubated with IgG4 F(ab’)2 (lane 4). These results indicated that IgG4
binds to IgG Fc by its own Fc, and not Fab as a classical RF. Experiments
were repeated three times with identical results.
doi:10.1371/journal.pone.0001637.g002
A Novel RF
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arthritis patient) to IgG is through their respective constant
segments and not Fab-Fc [40]. This is in direct support of our
results obtained on total seric, polyclonal, IgG4. Finally the fact
that IgG4 anti-immunoglobulin antibodies have been found in all
human beings puts the pathophysiological relevance of the here
presented data into perspective [41]. It is equally noteworthy that
this IgG4 Fc–Ig Fc interaction extends beyond man to a number
of other animal IgG. Some such as mouse, rabbit, guinea pig,
bovine and goat, showed strong reactivity with human IgG4. On
Figure 3. Scattergram of serum levels of IgG4 bound to IgG1k myeloma protein. Similar results were seen with assay systems for IgG4
bound to IgG2 k and IgG3 k myeloma proteins.
doi:10.1371/journal.pone.0001637.g003
Table 1. Serum levels of IgG4 binding to each IgG subclass in patients with autoimmune pancreatitis and various other conditions.
Patients and controls Anti-IgG1 (IgG4 mg/dl) Anti-IgG2 (IgG4 mg/dl) Anti-IgG3 (IgG4 mg/dl)
median
(range)
p (v.s.
autoimmune
pancreatitis)
Median
(range)
p (v.s.
autoimmune
pancreatitis)
Median
(range)
p (v.s.
autoimmune
pancreatitis)
Autoimmune pancreatitis (n=65) 296 (0–4,185) 306 (0–3,968) 142 (0–4,995)
Healthy subjects (n=130) 0 (0–57) ,0.0001 0 (0–59) ,0.0001 0 (0–0) ,0.0001
Chronic pancreatitis (n=111) 4 (0–635) ,0.0001 0 (0–435) ,0.0001 0 (0–901) ,0.0001
Pancreatic cancer (n=96) 2 (0–289) ,0.0001 2 (0–134) ,0.0001 0 (0–346) ,0.0001
Autoimmune hepatitis (n=40) 0 (0–761) ,0.0001 1 (0–414) ,0.0001 1 (0–214) ,0.0001
Primary biliary cirrhosis (n=39) 1 (0–71) ,0.0001 1 (0–147) ,0.0001 0 (0–24) ,0.0001
Primary sclerosing cholangitis (n=20) 1 (0–73) ,0.0001 5.5 (0–84) ,0.0001 0 (0–97) ,0.0001
Progressive systemic sclerosis (n=3) 0 (0–1) 0.0048 0 (0–0) 0.0041 0 (0–97) 0.0504
Sjo ¨gren’s syndrome (n=7) 0 (0–6) ,0.0001 8 (0–13) ,0.0001 0 (0–0) ,0.0001
Systemic lupus erythematosus (n=13) 1 (0–2) ,0.0001 1 (0–69) ,0.0001 0 (0–178) ,0.0001
Mann-Whitney test, autoimmune pancreatitis; autoimmune pancreatitis.
doi:10.1371/journal.pone.0001637.t001
A Novel RF
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to human IgG4 (unpublished data).
What is the raison d’e ˆtre of NRF? Is it beneficial or detrimental to
the disease process? Is it limited to IgG4 or could be found for
other IgG subclasses or Ig classes? Is it restricted to autoimmune
pancreatitis or of more general relevance ? A few clues could be
presented here. Firstly, one should be reminded of some structural
specificities of IgG4, paramount among which are its inability to
engage C1q, hence preventing it to activate the classical
complement pathway and dynamic in vivo exchange of Fab arms
leading to bispecific antibodies [22,42] (see infra). Secondly, there is
presently no reason to support for NRF to be limited to
autoimmune pancreatitis and given the relevance of IgG4 in a
vast array of other disorders, it is logical to assume NRF
Figure 4. CRF vs. NRF. (a) Correlation between serum levels of IgG4 bound to IgG1 and IgG4 value. A significant correlation was found. (b)
Correlation between serum levels of IgG4 bound to IgG1 and those of RF. No significant correlation was found.
doi:10.1371/journal.pone.0001637.g004
Figure 5. A Novel RF. Schematic representation of two distinct modes of Ig-Ig interaction. On the left: IgG4 Fc interacts with Ig Fc. On the
right: IgM RF recognizes IgG in a ‘‘classical’’ Fab-Fc recognition.
doi:10.1371/journal.pone.0001637.g005
A Novel RF
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of autoimmune pancreatitis, the following disorders for most
prevalent and relevant both in terms of frequency as well as public
health implications. They include membranous nephropathy, a
prevalent etiology of end-stage renal failure, is characterized by
deposit of IgG4 along the epithelia surface of glomerular basement
membrane [43]. Along with IgE, IgG4 has been reported to be
elevated in several helminthiasis [23] as well as allergic disorders
[24]. Finally in line with pemphigus where anti-desmoglein
antibodies have been established as pathogenic, patients develop-
ing toxic liver hepatitis or idiosyncratic drug induced hepatitis
have been shown to carry anti-cytochrome CYP21E IgG4
autoantibodies [25]. Finally it should be noted that NRF is
specific of IgG4 as none of the other IgG subclasses were found to
show such activity (unpublished data).
In more general terms and despite the fact that is is likely
premature to speculate much on the physiological/pathological
effects of IgG4 Fc-IgG Fc complexes in vivo, several not exclusive
situations could be envisioned based on circumstantial evidences.
(1) IgG4 Fc-Fc binding may have a pathological role within the
inflammatory process, or even induce inflammation per se.A n
example among may: In a mouse lupus nephritis model,
aggregated immunoglobulins react with fibronectin physicochem-
ically; this reaction in turn causes clustering of integrins and
internalization of immunoglobulins by glomerular endothelial
cells, resulting in fine in glomerular injury [44]. IgG4 Fc-Fc
binding may therefore indeed induce aggregation of immuno-
globulins. However, to date, there have been few reports
indicating IgG4 deposition in the affected pancreatic tissue,
therefore not in support of a direct immnopathological role of
IgG4 Fc-IgG Fc binding. (2) Alternatively, IgG4 may aid in the
clearance of immune complexes by forming larger complexes that
are more effectively cleared. In AIP there are high levels of serum
immune complexes that can be linked to complement activation.
In addition, we previously found that immune complexes detected
by monoclonal rheumatoid factor method also showed IgG4
activity [21]. Possibly, IgG1-type immune complexes trigger the
complement activation system via the classical pathway, and that
IgG4 contributes to the clearance of immune complexes and the
termination of the inflammatory process [45]. (3) Another
possibility is that IgG4 could block Fc-mediated effector functions
of other IgG1 and IgG3 and may dampen the inflammatory
response. (4) Finally it might be of interesting to pursue a recent
report with regards to IgG4 where authors document the in vivo
heavy (and light) chain swapping leading for unique biological
properties including cross-linking of 2 distinct antigens. This adds
to the already mentioned unique properties of IgG4 and may have
physiological, pathological as well as therapeutic consequences
(given that a number of therapeutic monoclonal antibodies are of
IgG4 isotype).
In conclusion, a sequential set of experiments, aimed initially to
confirm the mode of interaction of supposedly RF-like autoanti-
bodies to their cognate autoantigens revealed the unexpected fact
that IgG4 autoantibodies interact in vivo with IgG autoantigen in
an unprecedented topology. This Fc-Fc interaction departs from
the present definition of RF as a Fab-Fc interaction hence the
proposed dichotomic nomenclature of CRF vs. NRF. The fact that
IgG4 autoantibodies have been universally found in man [41] and
in the diverse set of above mentioned pathologies sets the agenda
for further characterization of NRF both in physiology as well as
pathology.
Supporting Information
Figure S1 Detailed protocol for generation of IgG fractions.
Found at: doi:10.1371/journal.pone.0001637.s001 (0.06 MB
DOC)
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